JW Therapeutics Reports 19.3% YOY Revenue Growth in 2023, Driven by CAR-T Therapy Carteyva
China-based JW Therapeutics (HKG: 2126) has announced its financial results for 2023, with revenues reaching...
MSD Reports USD 15.8 Billion in Q1 2024 Sales, Marked by 11% YOY Growth Excluding Forex Impact
Merck, Sharp & Dohme (MSD; NYSE: MRK) has released its financial report for the first...
Hua Medicine Reports 2023 Revenues of RMB 76.6 Million, Driven by Hypoglycemic Agent HuaTangNing
China-based biopharmaceutical company Hua Medicine (HKG: 2552) has released its financial report for 2023, with...
Yantai Lannacheng Biotech Secures RMB 300 Million in Series B+ Financing Round
Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has announced that its controlling subsidiary, Yantai...
Huadong Medicine’s Lidocaine-Containing Hyaluronic Acid Gel Accepted for NMPA Review
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that the National Medical Products Administration...
China’s NHC to Assume Management of Human Genetic Resources from May 2024
The National Health Commission (NHC) of China has announced that the State Council has approved...
Chia Tai Tianqing’s TQA3038 siRNA Drug Completes Phase I Clinical Trial for Chronic Hepatitis B
Chia Tai Tianqing has announced the successful completion of a Phase I clinical study for...
US FDA Greenlights Henlius Biotech’s Hanquyou as Biosimilar to Roche’s Herceptin
Shanghai Henlius Biotech Inc. (HKG: 2696) has achieved a significant milestone with the US Food...
Sanofi Reports 6.7% YOY Sales Growth in Q1 2024, Driven by Dupixent and New Product Launches
France-based pharmaceutical giant Sanofi (NASDAQ: SNY) has reported its financial results for the first quarter...
Novartis Receives Positive Interim Results for Antimalarial Coartem in Infants
Swiss pharmaceutical company Novartis (NYSE: NVS) has announced interim results from a Phase II/III clinical...
Bristol Myers Squibb Reports 6% YOY Revenue Growth in Q1 2024, Driven by Eliquis and Reblozyl
Pharmaceutical giant Bristol Myers Squibb (BMS; NYSE: BMY) has reported a 6% year-on-year (YOY) increase...
Roche’s Q1 2024 Turnover Rises 2% YOY, Driven by New Medicines and Diagnostics
Swiss pharmaceutical and diagnostics giant Roche (SWX: ROG) has reported a 2% year-on-year (YOY) increase...
Gan & Lee Pharmaceuticals Reports 52.31% YOY Revenue Growth in 2023, Driven by Insulin Sales
Gan & Lee Pharmaceuticals (SHA: 603087) has announced its financial results for 2023, reporting a...
Novartis Becomes First MNC to Publicly Adjust China CRDMO Partnerships in Response to BioSecure Act
Swiss pharmaceutical giant Novartis (NYSE: NVS) has reportedly become the first multinational corporation to publicly...
Insilico Medicine Partners with invoX Pharma to Boost AI-Driven Drug Discovery
China’s generative artificial intelligence (AI)-driven biotech firm Insilico Medicine has entered into a partnership with...
Hebei Changshan Biochemical’s Albenatide File for Type 2 Diabetes Accepted by China’s NMPA
Hebei Changshan Biochemical Pharmaceutical Co., Ltd (CSBIO; SHE: 300255) has announced that the National Medical...
Betta Pharmaceuticals’ BPI-16350 Combo Therapy Shows Improved PFS in Breast Cancer Trial
China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) has announced an update on its Phase III...
MicroPort MedBot Reports 384.2% YOY Revenue Increase in 2023, Driven by Robotic Surgical Devices
Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) has announced its financial results for 2023,...
Novartis’s Lutathera Secures FDA Approval for Pediatric Gastroenteropancreatic NETs
The US Food and Drug Administration (FDA) has granted regulatory approval to Novartis (NYSE: NVS)...
Hubei Province Issues Anti-Commercial Bribery Guidelines for Medical Industry
The Hubei provincial market supervision administration has released a set of guidelines titled “Anti-Commercial Bribery...